Prenatal olanzapine exposure and congenital talipes equinovarus (clubfoot): a case report and review of emerging evidence

Submitted: 2024 July 15
Accepted: 2024 July 19
Published: 2024 July 24
Abstract Views: 109
PDF: 56
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Mohsen Khosravi dr_khosravi2016@yahoo.com Department of Psychiatry, School of Medicine, Zahedan University of Medical Sciences; Health Promotion Research Center, Zahedan University of Medical Sciences, Iran, Islamic Republic of.

Recently, concerns have emerged about the potential teratogenic effects of olanzapine, particularly its association with congenital malformations such as congenital talipes equinovarus (clubfoot). Evidence from a large Finnish study, which reported a 2.5-fold increase in musculoskeletal anomalies, as well as various case reports, suggests a significant link between in-utero exposure to olanzapine and these anomalies. This case report aims to add to the growing body of evidence by detailing a new instance of clubfoot following prenatal olanzapine exposure. A 25-year-old woman suffering from bipolar I disorder with psychotic features was treated with olanzapine during pregnancy, resulting in the birth of a male infant with clubfoot but no other malformations. This case underscores the importance of careful risk assessment and monitoring for pregnant women undergoing psychiatric treatment with olanzapine. Potential mechanisms, such as disrupted fetal musculoskeletal development due to olanzapine’s pharmacological effects, warrant further investigation. Comparative analysis with other cases highlights consistent patterns, emphasizing the need for further research to elucidate the mechanisms and risk factors involved.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA 2023;330:1370-80. DOI: https://doi.org/10.1001/jama.2023.18588
Ortega MA, Pekarek T, Fraile-Martinez O, et al. A review: integrative perspectives on the features and clinical management of psychotic episodes in pregnancy. J Clin Med 2023;12:656. DOI: https://doi.org/10.3390/jcm12020656
Andrade C. Major congenital malformations associated with exposure to second-generation antipsychotic drugs during pregnancy. J Clin Psychiatry 2021;82:21f14252. DOI: https://doi.org/10.4088/JCP.21f14252
FDA. MedWatch: the FDA safety information and adverse event reporting program. Available from: www.fda.gov/medwatch
Ellfolk M, Leinonen MK, Gissler M, et al. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol 2021;77:1737-45. DOI: https://doi.org/10.1007/s00228-021-03169-y
Viguera AC, Freeman MP, Góez-Mogollón L, et al. Reproductive safety of second-generation antipsychotics: updated data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry 2021;82:20m13745. DOI: https://doi.org/10.4088/JCP.20m13745
Gyawali R, Baral A, Upreti D, et al. Novel report on congenital talipes equinovarus (CTEV) following olanzapine exposure during pregnancy: case report and short review. Arch Womens Ment Health 2022;25:671-4. DOI: https://doi.org/10.1007/s00737-022-01221-z
Agarwal S, Dahuja M, Tyagi M. Risks associated with psychotropic drugs during pregnancy. Ann Indian Psychiatry 2018;2:58-60. DOI: https://doi.org/10.4103/aip.aip_30_17
Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry 2007;164:1759-60. DOI: https://doi.org/10.1176/appi.ajp.2007.07010176
Dimeglio A, Bensahel H, Souchet PH, et al. Classification of clubfoot. J Pediatr Orthop B 1995;4:129-36. DOI: https://doi.org/10.1097/01202412-199504020-00002
Louchet M, Tisseyre M, Kaguelidou F, et al. Drug-induced fetal and offspring disorders, beyond birth defects. Therapie 2024;79:205-19. DOI: https://doi.org/10.1016/j.therap.2023.11.002
Huybrechts KF, Straub L, Karlsson P, et al. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry 2023;80:156-66. DOI: https://doi.org/10.1001/jamapsychiatry.2022.4109
Stanisavljevic A, Peric I, Pantelic M, et al. Olanzapine alleviates oxidative stress in the liver of socially isolated rats. Can J Physiol Pharmacol 2017;95:634-40. DOI: https://doi.org/10.1139/cjpp-2016-0598
Chen C, Kaushal N, Scher DM, et al. Clubfoot etiology: a meta-analysis and systematic review of observational and randomized trials. J Pediatr Orthop 2018;38:e462-9. DOI: https://doi.org/10.1097/BPO.0000000000001191
Soares MA, Costa AL, Silva NL, et al. Atypical antipsychotics olanzapine and clozapine increase bone loss in female rats with experimental periodontitis. J Periodontal Res 2023;58:283-95. DOI: https://doi.org/10.1111/jre.13090
Disha-Ibrahimi S, Furlani B, Drevenšek G, et al. Olanzapine decreased osteocyte maturation and Wnt/β-catenin signaling during loading of the alveolar bone in rats. Biomol Biomed 2023;23:114-25. DOI: https://doi.org/10.17305/bjbms.2022.7523

How to Cite

1.
Khosravi M. Prenatal olanzapine exposure and congenital talipes equinovarus (clubfoot): a case report and review of emerging evidence. Mental Wellness [Internet]. 2024 Jul. 24 [cited 2024 Dec. 6];2(1). Available from: https://www.mental-wellness-journal.net/mw/article/view/14